Using EsophaCap Capsule to Detect Early Barretts Esophagus, Esophageal Carcinoma, and Gastric Cancer

What this Trial Is About

Researchers are studying biomarkers for early detection of Barretts Esophagus, esophageal carcinoma including adenocarcinoma and squamous cell carcinoma, and gastric cancer. The goal is to find markers that can differentiate between these conditions and normal esophageal or gastric tissue, helping to identify these diseases sooner. This observational study collects cytology samples using a sponge capsule to analyze DNA and test candidate genes as potential biomarkers. The study involves collecting esophageal and gastric cell samples through a swallowed sponge capsule. Participants include adults over 18 who have undergone esophagogastroduodenoscopy and fall into different groups those without Barretts esophagus or cancer, those diagnosed with Barretts esophagus, those with esophageal carcinoma, and those with gastric cancer. The DNA from these samples will be analyzed to find differences in gene methylation that could serve as biomarkers. Participants will be assessed through the sponge capsule procedure and the analysis of collected samples. Researchers will measure differences in gene methylation to distinguish disease states from normal tissue. They will also evaluate the sensitivity and specificity of several candidate biomarkers, such as p16, NELL1, AKAP12, TAC1, and HPP1. The study is conducted over a long period, with the main outcome measurements typically done within one day after sample collection.

EsophaCap for the Detection of Early Esophageal Carcinoma